1. Hatzakis A et al.. J Virol Hepat 2011; 18 (s1):1–16
  2. Cornberg M et al Liver International 31 Suppl 2:30-60 DOI:10.1111/j.1478-3231.2011.02539.x* Epidemiology and Patient Demographics: Gilead HCV Ex-US Epidemiology Research, May 2012; 2Ipsos HCV Monitor Q2 2012’Population: 3WHO data (2009).
    Ipsos data will be used in 2013 and beyond to capture key epidemiology and patient demographics for under treater care patient population, which will differ from the current overall epidemiology numbers.
    A prevalência e distribuição de genótipos para Portugal é proveniente de Ramalho F, Costa A, Pires A, et al.
    Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. Dig Dis Sci 2000; 45: 182–7.
  3. Hoofnagle J. Hepatology 1997; 26:15-20;
  4. Anjo J. Et Al “impacto dda Hepatite C em Portugal”; 16.ª Annual Meeting of the Portuguese Association for the Study of the Liver, Abril 5-6th 2013 P40:
  5. Lee MH et al, Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study, J Infect Dis. 2012; 206(4):469-77
  6. Smith BD et al, Recommendations for the identification of chronic Hepatitis C virus infection among persons born during 1945–1965, MMWR Recomm Rep 2012; 61(4):1-32.
  7. Soriano V, et al, Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C, J Antimicrob Chemother 2008; 62(1):1-4